Product Description
Netarsudil ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Netarsudil is in a class of medications called rho kinase inhibitors. It works by lowering the pressure in the eye by increasing the flow of natural eye fluids out of the eye.
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Slovakia | Sweden | United Arab Emirates | United Kingdom | United States
Approved Indications: Hypertension | Glaucoma | Glaucoma, Open-Angle
Known Adverse Events: Hyperemia | Pain Unspecified
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Glaucoma|Hypertension
Phase 2: Glaucoma, Open-Angle
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GLR305-E001 | P2 |
Recruiting |
Glaucoma, Open-Angle|Hypertension |
2025-11-01 |
|
| jRCT2031210125 | P3 |
Recruiting |
Glaucoma |
2025-03-31 |
|
| jRCT2031210122 | P3 |
Completed |
Glaucoma|Hypertension |
2022-05-02 |